TARBP2 and hepatocellular carcinoma: C4‐domain‐truncated TARBP2 was used to disrupt the binding between TARBP2 and Dicer and block miRNA biogenesis (Daniels et al., 2009) to investigate whether the TARBP2‐enhanced sensitivity of HCC cells to sorafenib treatment is miRNA‐dependent (Fig. 2I,J).